Esperion Therapeutics (Nasdaq: ESPR) shares are on watch following the U.S. FDA's approval of Amgen's (Nasdaq: AMGN) Repatha Injection for ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE